Dulaglutide: Discovery, Development, Safety and Pharmacovigilance

A lifecycle account of dulaglutide from Fc-fusion engineering and type 2 diabetes trials through cardiovascular outcomes, regulatory changes, delivery devices and practical pharmacovigilance.

Take test

Dulaglutide: Discovery, Development, Safety and Pharmacovigilance

Dulaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly for type 2 diabetes mellitus. Its molecular engineering solved a practical problem: native GLP-1 is rapidly degraded, whereas a modified GLP-1 analogue fused to an immunoglobulin Fc region can provide prolonged exposure suitable for once-weekly administration. Its development also shows why glucose-lowering efficacy, cardiovascular outcome evidence and safety surveillance must be evaluated separately. Improvements in HbA1c do not automatically establish a cardiovascular benefit, and a class warning does not establish an event's incidence in humans [1–4]. This article follows that evidence sequence before explaining the authorised uses, safety controls and pharmacovigilance decisions that arise from it.

Discovery and molecular engineering

Native GLP-1 is secreted by intestinal L cells after food intake and stimulates glucose-dependent insulin secretion, suppresses glucagon when glucose is elevated, slows gastric emptying and affects appetite. Its short biological half-life makes it impractical as an unmodified once-weekly treatment. Lilly's programme used a GLP-1 analogue engineered to resist degradation by dipeptidyl peptidase-4 (DPP-4) and fused it to an Fc fragment of human IgG4. The construct has two GLP-1 analogue chains linked to an Fc scaffold, producing a large molecule with slow clearance [2,4].

The fusion strategy is pharmacologically important: the Fc domain contributes to the molecule's extended exposure but does not turn dulaglutide into a monoclonal antibody therapy directed at a separate antigen. The intended target remains the GLP-1 receptor. The 2010 engineering report described LY2189265, the development code for dulaglutide, and demonstrated receptor activity and sustained glucose-dependent effects in preclinical models. Those experiments supported human development; they were not clinical proof of cardiovascular protection. Early translational work explored whether this architecture could provide glycaemic control with infrequent injections, while managing immunogenicity and gastrointestinal tolerability [2].

Mechanism and disposition

Dulaglutide binds and activates GLP-1 receptors, enhancing glucose-dependent insulin release and reducing inappropriate glucagon secretion. Because its insulinotropic effect is glucose-dependent, severe hypoglycaemia is less frequent when used alone than with insulin or insulin secretagogues; concomitant sulfonylureas or insulin can materially increase risk. Gastric emptying is delayed, which may influence absorption of oral medicines and complicate the management of severe gastrointestinal illness [1].

The US prescribing information describes a terminal elimination half-life of approximately five days, supporting once-weekly administration. Steady state is achieved after roughly two to four weeks of weekly dosing. It is administered subcutaneously, not intravenously or orally. Pharmacovigilance should distinguish pharmacological persistence from the timing of the most recent injection, particularly when assessing vomiting, dehydration or a perioperative aspiration event [1].

Clinical development: AWARD programme

AWARD-1 and comparative glycaemic control

The Assessment of Weekly Administration of LY2189265 in Diabetes (AWARD) programme compared dulaglutide with placebo and established diabetes therapies. AWARD-1 evaluated once-weekly dulaglutide against exenatide twice daily and placebo in patients using metformin and pioglitazone. Dulaglutide improved HbA1c relative to placebo and met prespecified comparisons with the active treatment [5]. The trial supports glycaemic efficacy in a defined treatment context; it does not establish superior outcomes for all complications of diabetes.

AWARD-2 and AWARD-6

AWARD-2 compared dulaglutide with insulin glargine in patients receiving metformin and glimepiride. HbA1c and weight effects differed between groups, while hypoglycaemia interpretation depended on background sulfonylurea use [6]. AWARD-6 was a head-to-head noninferiority study against once-daily liraglutide. Dulaglutide 1.5 mg met the trial's noninferiority criterion for HbA1c reduction, but the design does not support broad superiority claims across cardiovascular, renal or weight outcomes [7].

AWARD-7: chronic kidney disease

AWARD-7 studied patients with type 2 diabetes and moderate-to-severe chronic kidney disease receiving prandial insulin. Dulaglutide and insulin glargine achieved similar glycaemic control, while eGFR trajectories differed. This trial is relevant to treatment in patients with kidney impairment but does not remove the need to monitor renal function during dehydration from severe gastrointestinal reactions [8].

Cardiovascular outcome evidence: REWIND

REWIND was a randomised, placebo-controlled cardiovascular outcomes trial involving 9,901 adults with type 2 diabetes and either previous cardiovascular events or cardiovascular risk factors. Over a median 5.4-year follow-up, the primary composite of nonfatal myocardial infarction, nonfatal stroke or cardiovascular death occurred in 12.0% of dulaglutide-treated participants and 13.4% of placebo-treated participants (hazard ratio 0.88, 95% CI 0.79–0.99) [9]. The absolute difference and follow-up period matter; the hazard ratio should not be described as an individual patient's guaranteed 12% reduction in events.

The trial supported a US label indication to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors [1]. Its relatively broad risk population differs from cardiovascular trials enrolling only patients with prior events. The trial's outcome evidence should not be conflated with HbA1c lowering or extended to unstudied populations.

Higher-dose development: AWARD-11

AWARD-11 evaluated dulaglutide 3.0 mg and 4.5 mg once weekly against 1.5 mg in patients inadequately controlled on metformin. Higher doses produced additional HbA1c and weight effects, accompanied by dose-related gastrointestinal adverse events [10]. The escalation schedule is important to tolerability; starting immediately at the highest dose would not reproduce the trial's exposure pattern. A case report should record the pen strength, escalation dates and actual administered dose rather than relying on a medication list that may show only the latest prescription.

Later comparative evidence: SURPASS-CVOT

Dulaglutide subsequently became an active comparator in the SURPASS-CVOT cardiovascular outcomes trial, published in December 2025. Patients with type 2 diabetes and established atherosclerotic cardiovascular disease received tirzepatide up to 15 mg weekly or dulaglutide 1.5 mg weekly. Tirzepatide met the trial's noninferiority criterion for the composite of cardiovascular death, myocardial infarction or stroke [11]. This answers a different question from REWIND: comparison with an established active treatment rather than comparison with placebo.

Noninferiority is defined by a prespecified statistical margin; it is not proof that the medicines are identical. The result also does not compare tirzepatide with dulaglutide 3.0 mg or 4.5 mg. Comparative benefit–risk interpretation must retain the enrolled cardiovascular-risk population, dose, endpoint and study design rather than transfer a headline result to all incretin treatments. See the separate tirzepatide lifecycle article for its development context.

Authorisation, dosing and commercial lifecycle

FDA's Purple Book records original US approval on 18 September 2014, with Eli Lilly and Company as applicant; the EU authorisation dates from 21 November 2014 [3,4]. Lilly's in-house engineering programme and subsequent commercialisation illustrate a protein-platform strategy: prolonged exposure and a weekly delivery device were developed together with the clinical evidence. Competition from other incretin treatments later changed the market context. This history does not establish an INN sales ranking, and no unverified revenue or market-share figures are used here.

The current US prescribing information reviewed for this article is revised March 2026. EU interpretation uses the EMA product information available at review. These documents should be read separately: the presence of cardiovascular results in the European SmPC is not the same as a separately worded US cardiovascular-risk-reduction indication [1,4].

Issue United States European Union
Authorised population Glycaemic control in type 2 diabetes from age ten; a separate cardiovascular-risk-reduction indication in specified adults Insufficiently controlled type 2 diabetes from age ten, as monotherapy when metformin is unsuitable or in addition to other diabetes medicines
Adult starting regimen 0.75 mg weekly; may increase after four weeks to 1.5 mg, then in 1.5-mg increments after at least four weeks at each dose Recommended monotherapy dose 0.75 mg weekly; add-on dose 1.5 mg weekly, with increases to 3 mg and then 4.5 mg after at least four weeks at each step
Paediatric regimen Start 0.75 mg weekly; maximum 1.5 mg weekly after at least four weeks if needed Same starting dose and maximum; adult higher doses are not the paediatric regimen
Thyroid warning Boxed C-cell tumour warning; MTC/MEN2 contraindications US boxed-warning terminology and MTC/MEN2 contraindications must not be imported into EU section 4.3, which lists hypersensitivity
Severe kidney impairment No dosage adjustment recommended, including end-stage renal disease, with caution and renal monitoring when fluid depletion occurs No adjustment down to eGFR 15 mL/min/1.73 m²; not recommended below 15 because experience is very limited

The adult maximum is 4.5 mg weekly in both regions. Dulaglutide is not a treatment for type 1 diabetes or diabetic ketoacidosis and is not a replacement for insulin. The EU SmPC describes ketoacidosis after rapid insulin discontinuation or dose reduction. Consequently, a report after switching treatment needs the insulin-change history as well as dulaglutide exposure [1,4].

Exposure, interactions and administration

The weekly schedule creates specific medication-error risks. The authorised missed-dose instructions permit a delayed dose only when at least 72 hours remain before the next scheduled injection; otherwise it is skipped. Changing the weekly day likewise requires at least 72 hours between doses [1,4]. These instructions should not be converted into an assumption that any shorter interval necessarily produces toxicity: the actual dose, interval and clinical effects must be assessed.

Dulaglutide is a protein degraded through general protein-catabolism pathways. Its important interaction questions concern glucose lowering and gastric emptying rather than a conventional CYP inhibition profile. Delayed absorption does not necessarily mean reduced total exposure. The EU SmPC documents studies of medicines including warfarin and an oral contraceptive without clinically relevant changes requiring dose adjustment in the tested conditions; the US label advises monitoring narrow-therapeutic-index oral medicines such as warfarin [1,4]. A class-wide claim that dulaglutide invariably makes oral contraception ineffective would therefore be inappropriate. Vomiting or diarrhoea may nevertheless create a separate absorption or adherence problem.

These distinctions establish the context for safety assessment. A reaction may arise from the molecule's pharmacology, the dose-escalation pattern, another glucose-lowering medicine, the injection device, or the underlying diabetes. They should remain distinguishable in both an individual narrative and aggregate analysis.

Listedness against the USPI and EU SmPC

This comparison concerns Trulicity dulaglutide solution for subcutaneous injection in single-dose prefilled pens, including the 0.75-, 1.5-, 3- and 4.5-mg presentations. The sources are Lilly's USPI revised March 2026 [1] and the EMA EU product-information document whose EPAR update is dated 30 January 2026 [4], both accessed on 26 October 2026. The paediatric maximum remains 1.5 mg weekly, and the authorised indication and adult starting-dose differences are set out above.

For this public-label comparison, “listed” means that the named document includes the reaction or safety information in the specified section. A warning, a clinical-trial observation and a tabulated adverse reaction are identified separately; their presence does not establish the same regulatory status or frequency.

Safety subject March 2026 USPI January 2026 EU SmPC
Nausea, diarrhoea and vomiting Listed in section 6.1 trial adverse-reaction data; rates depend on dose and trial pool Listed as very common in section 4.8; the table and dose-specific narrative should be read together
Hypoglycaemia Listed in sections 5.3 and 6.1 with concomitant-treatment context Listed in section 4.8 with frequency depending on background therapy; section 4.4 addresses insulin/sulphonylurea risk
Pancreatitis Listed in section 5.2 and postmarketing section 6.2, including severe forms Acute pancreatitis is listed as rare in section 4.8, with management instructions in section 4.4
Intestinal motility disorders Ileus, intestinal obstruction and severe constipation including faecal impaction are listed in section 6.2; a reliable spontaneous-report frequency cannot be assigned Non-mechanical intestinal obstruction is listed with frequency not known in section 4.8; constipation is separately listed as common
Gallbladder events Cholecystitis and cholelithiasis appear in sections 5.8 and 6.2 Cholelithiasis and cholecystitis are listed as uncommon in section 4.8
Retinopathy complications Described in section 5.7 and cross-referenced from section 6; a warning supported by cardiovascular-trial observations Not listed as a named adverse reaction in the assessed section 4.8 table and no corresponding retinopathy warning was identified in the reviewed SmPC
Aspiration with anaesthesia/deep sedation Addressed in section 5.9 and cross-referenced from section 6 Addressed in section 4.4 as a procedural warning; this is distinct from a frequency category in section 4.8

The US boxed thyroid warning and MTC/MEN2 contraindications are additional material differences, already explained above. They should not be reclassified as proof of a human adverse reaction merely because the nonclinical finding is prominent in the label. Conversely, an event's absence from the assessed EU table is not proof that it cannot occur.

These conclusions are limited to the named public documents and review date. They do not determine company-core listedness, expectedness for an individual report against its applicable reference safety information, causality, seriousness or a submission obligation. Those decisions require the applicable document version, event specificity and reporting context. The distinction is developed further in listedness, expectedness and reference safety information.

Boxed warning: thyroid C-cell tumours

The US Trulicity label carries a boxed warning that dulaglutide caused thyroid C-cell tumours in rats and that its relevance to humans is unknown. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2) [1]. The warning must not be rewritten as proof that dulaglutide causes MTC in humans. Routine calcitonin measurement or thyroid ultrasound has uncertain value for early MTC detection under the US label; evaluation of suspicious symptoms or findings remains clinically appropriate.

A thyroid-cancer report should capture the histological type, timing relative to exposure, family history, MEN2 status and relevant pre-existing disease. Pooling all thyroid malignancies into a single outcome can obscure the distinction between C-cell and follicular-cell tumours.

Pancreatitis and pancreatic safety

Acute pancreatitis has been reported during dulaglutide treatment, including postmarketing cases. Product information advises observation for severe persistent abdominal pain, sometimes radiating to the back, with or without vomiting; the US label directs discontinuation when pancreatitis is suspected; the EU SmPC additionally states that it should not be restarted if pancreatitis is confirmed [1,4]. Diabetes, gallstones, alcohol exposure and hypertriglyceridaemia are important competing causes.

A medically useful case includes symptom onset, lipase or amylase results, imaging, diagnostic criteria, gallstone assessment, triglycerides, alcohol history, concomitant drugs and outcome. An isolated mild enzyme elevation without symptoms or imaging does not by itself establish acute pancreatitis. Signal detection must distinguish reporting frequency from population incidence.

Gastrointestinal reactions and dehydration

Nausea, vomiting, diarrhoea, abdominal discomfort and reduced appetite are prominent adverse reactions, especially during initiation or escalation. Severe or persistent symptoms can cause dehydration and acute kidney injury. The March 2026 US label advises renal monitoring when adverse reactions could cause volume depletion, especially during initiation and escalation [1]. Patients with severe gastroparesis are a particularly important group because dulaglutide delays gastric emptying and is not recommended in severe gastroparesis under US product information.

The current US postmarketing section also includes ileus, intestinal obstruction and severe constipation including faecal impaction. Such spontaneous reports do not establish frequency or causality; persistent vomiting, abdominal distension and failure to pass stool require clinical investigation rather than routine coding as uncomplicated nausea [1]. The EU adverse-reaction table includes non-mechanical intestinal obstruction with frequency not known [4].

An adverse-event record should reconstruct the actual titration schedule, food intake, fluid loss, blood pressure, renal function and other causes. Hospitalisation for dehydration should not be reduced to a non-serious nausea report merely because nausea is a labelled event.

Hypoglycaemia in combination treatment

Dulaglutide used without insulin or insulin secretagogues has a lower intrinsic tendency to cause hypoglycaemia than treatments that stimulate insulin independently of glucose. However, adding it to sulfonylureas or insulin may require dose reduction of those agents [1]. Case follow-up should document measured glucose, severity, need for assistance, meal timing, kidney function, background drugs and whether a dosing change preceded the episode.

The distinction between a low glucose measurement, symptomatic hypoglycaemia and severe hypoglycaemia requiring external assistance is important in clinical trials and spontaneous reports. These outcomes should not be combined without an explicit case definition.

Gallbladder disease and biliary events

Gallbladder events, including cholelithiasis and cholecystitis, have been reported in GLP-1 receptor agonist programmes. The US label advises gallbladder diagnostic studies and clinical follow-up when cholelithiasis is suspected [1]. Weight loss itself may influence gallstone risk, and underlying diabetes adds complexity. Cases should capture ultrasound findings, biliary obstruction, liver tests, weight trajectory and surgical outcomes.

Hypersensitivity and immunogenicity

Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported. Dulaglutide is a protein therapeutic and can elicit antidrug antibodies, although the clinical significance of individual antibody findings depends on assay characteristics and context [1]. A suspected anaphylaxis report should document time from injection to symptoms, airway and cardiovascular findings, treatment and other potential triggers.

Do not treat a positive antidrug-antibody test as equivalent to neutralising activity or clinical treatment failure. Comparisons of immunogenicity percentages across unrelated products are especially vulnerable to differences in assay sensitivity, sampling and definitions.

Retinopathy, vision and glycaemic change

Diabetic retinopathy complications were reported in REWIND, especially in patients with a prior retinopathy history [1]. Rapid improvement in glycaemic control can itself influence retinopathy course. Case assessment should include baseline eye disease, HbA1c trajectory, retinal findings, ophthalmological treatment and alternative explanations. This is not a basis for assuming every new visual symptom is drug-induced.

Aspiration during anaesthesia or deep sedation

Delayed gastric emptying may leave residual gastric contents despite fasting. The US label includes reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists during general anaesthesia or deep sedation [1]. Perioperative recommendations have evolved, and no single universal interruption interval should be invented from spontaneous reports. A case should record the last dose, fasting history, procedure, anaesthetic approach, symptoms, airway findings and outcome.

Pregnancy, lactation and paediatric use

Animal reproductive studies identified potential fetal harm, and human pregnancy data are insufficient to establish safety. Decisions about treatment in pregnancy must account for maternal diabetes and current local product information [1]. The EU SmPC does not recommend use during pregnancy and states that dulaglutide should not be used during breastfeeding; the US label instead discusses potential benefit versus fetal risk and individual consideration of breastfeeding benefits, maternal need and possible infant risk [1,4]. These are jurisdiction-specific label positions, not evidence of established human reproductive safety.

Pregnancy-exposure surveillance should record timing by gestational week, dose, glycaemic control, co-medications, maternal complications and infant outcomes. A spontaneous report of an adverse birth outcome does not establish causality.

The US label includes use in children aged ten years and older with type 2 diabetes, based on a paediatric trial. The AWARD-PEDS study demonstrated improved HbA1c with dulaglutide 0.75 mg and 1.5 mg versus placebo at 26 weeks, with gastrointestinal adverse reactions more frequent in active-treatment groups [12]. Both reviewed labels limit paediatric dosing to 1.5 mg weekly; the adult 3.0-mg and 4.5-mg regimens are not authorised paediatric regimens [1,4]. Paediatric growth, nutritional status, adherence and injection technique merit careful assessment.

Device safety, administration and medication errors

Trulicity is supplied in single-dose prefilled pens. Device familiarity can improve adherence, but it also introduces distinct failure modes: wrong strength selected, dose administered twice, injection attempted through clothing, needle-cap errors, incorrect storage, or mistaken assumptions that a device fired successfully. Case narratives should record the product presentation, lot number when available, device condition, user training, storage history, actual dose and whether medication was delivered.

Higher-dose strengths increase the importance of avoiding confusion between weekly pens. A medication error is not necessarily an adverse reaction; the report should distinguish the error, any exposure and the clinical consequence. Product-quality complaints may require separate technical investigation and batch traceability.

Pharmacovigilance scenarios

Scenario 1: vomiting, dehydration and renal injury

Illustrative case, not a regulatory finding. A patient escalates dulaglutide and develops severe vomiting, reduced fluid intake and acute kidney injury. The reviewer reconstructs the dose schedule, timing of symptoms, weight and blood-pressure changes, creatinine trajectory, diuretics, intercurrent infection and management. The safety assessment separates the gastrointestinal reaction from its downstream renal complication and considers other causes of kidney dysfunction.

Scenario 2: pancreatitis in a patient with gallstones

Illustrative case. A patient reports abdominal pain and elevated lipase while receiving dulaglutide; imaging also reveals gallstones. Follow-up should establish whether accepted pancreatitis criteria are met, the role of biliary disease, exposure chronology and recovery after intervention. A labelled warning supports clinical vigilance, not automatic attribution in an individual case.

Scenario 3: wrong pen strength

Illustrative case. A patient intending to inject 1.5 mg uses a 4.5-mg pen. The report should distinguish the prescribed regimen, dispensed strength, actual injection, symptoms, intervention and contributing device or counselling factors. Record the error even if no harm occurs. For EU ICSR submission, an error without a suspected adverse reaction should not automatically be treated as a reportable ICSR solely because the wrong dose was given; it still warrants applicable medication-error and product-quality recording, investigation and aggregate review. When a suspected adverse reaction is present, assess ICSR validity, seriousness and submission obligations under the applicable framework [13].

Aggregate signal management

A mature GLP-1 safety programme combines spontaneous reports, trial extensions, observational studies, registries and regulatory communications. The main analytical challenges include confounding by diabetes severity, obesity, rapid glycaemic improvement, background insulin or sulfonylureas and differential attention to class safety concerns. Disproportionality findings can prioritise review but cannot supply incidence or causality without additional evidence.

Case definitions should be specific. For example, pancreatitis should be medically adjudicated where feasible; thyroid outcomes should distinguish MTC from other malignancies; aspiration reports should capture anaesthetic context; and renal events should identify preceding fluid loss. Exposure and dose-escalation denominators are important when interpreting time-to-onset patterns.

For EU pharmacovigilance operations, binding legislation governs the system's obligations, while GVP explains the conduct of case management, signal management and periodic benefit–risk evaluation. Commission Implementing Regulation (EU) No 520/2012 has been amended by Regulation (EU) 2025/1466. EMA notes that GVP revisions are following these amendments and that the EU implementation materials for ICH E2D(R1) must also be considered [13,14]. An operational team should therefore check the applicable implementation position rather than rely on an undated copy of a module. A suggested internal device-error taxonomy or standardised pancreatitis follow-up form is a quality practice unless mandated by a specific applicable requirement. Governance records should show the safety question, evidence sources, medical review, decision, implementation and evaluation.

Quality oversight and inspection evidence

A product-specific review should be able to follow one safety question from the original information to the final action. For a suspected injection-device defect, this means linking the safety case to the quality complaint, retaining the lot and device information where available, and reconciling clinical follow-up with the technical investigation. A quality investigation that concludes that a pen functioned as designed does not erase a medically significant reaction; likewise, a safety narrative cannot establish a manufacturing defect without technical evidence. Biological-product traceability is specifically addressed in the EU SmPC [4].

Responsibilities should be explicit within the marketing authorisation holder's quality system. Case-processing staff obtain and preserve the exposure and clinical information; medical reviewers assess the event and competing causes; device/quality specialists investigate the product complaint; and the safety-governance process evaluates whether recurring patterns require a signal assessment, label action, training or another control. The QPPV's oversight connects these activities to the wider pharmacovigilance system. These suggested operational interfaces do not create a new dulaglutide-specific legal role [13,14].

An inspector could examine whether the implemented process produces reliable evidence, rather than merely whether an SOP mentions GLP-1 medicines. The following are illustrative review questions, not reported inspection findings.

Safety question Evidence that could demonstrate an effective process
Are renal complications being recognised beyond the initial nausea report? Follow-up requests, creatinine and hydration history, medical assessment and documented seriousness decisions
Can device complaints and safety cases be reconciled? Linked identifiers, documented product and batch searches, quality-investigation outcome and clinical follow-up
Are regional label changes implemented consistently? Version-controlled reference information, change assessment, approved updates and evidence of implementation
Is a reporting increase a genuine new safety concern? Case definitions, duplicate review, dose/exposure context, confounder assessment and the recorded signal decision
Did an action address its intended problem? A defined objective, proportionate follow-up measures, review of results and escalation when performance remains inadequate

Such records support an assessment of traceability and effectiveness. A completion count or absence of overdue cases alone cannot establish that medical follow-up was adequate. Related principles are developed in causality assessment and drug-induced kidney injury.

Practical checklist

Key takeaways

Dulaglutide's engineered Fc-fusion structure enabled once-weekly GLP-1 receptor activation. The AWARD programme established glucose-lowering efficacy in defined populations; REWIND established a cardiovascular outcome benefit; and AWARD-11 supported higher-dose treatment with a distinct tolerability profile. Safety surveillance must address the boxed thyroid C-cell tumour warning, pancreatitis, gastrointestinal dehydration, hypoglycaemia in combination therapy, gallbladder disease, hypersensitivity, retinopathy, aspiration and device errors. Good pharmacovigilance is product-, dose-, population- and jurisdiction-specific.

References

  1. Eli Lilly and Company. Trulicity (dulaglutide): US Prescribing Information. Revised March 2026; sections 1–8 and 11–14. https://pi.lilly.com/us/trulicity-uspi.pdf
  2. Glaesner W, et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev. 2010;26:287–296. https://doi.org/10.1002/dmrr.1080
  3. US Food and Drug Administration. Purple Book: Trulicity, BLA 125469; original approval 18 September 2014. https://purplebooksearch.fda.gov/index.cfm?blaNo=125469&event=productdetails
  4. European Medicines Agency. Trulicity: EPAR and EU product information, particularly SmPC sections 4.1–4.8 and 5.1–5.3. https://www.ema.europa.eu/en/medicines/human/EPAR/trulicity ; https://www.ema.europa.eu/en/documents/product-information/trulicity-epar-product-information_en.pdf
  5. Wysham C, et al. Efficacy and safety of dulaglutide added to pioglitazone and metformin (AWARD-1). Diabetes Care. 2014;37:2159–2167. https://doi.org/10.2337/dc13-2760
  6. Giorgino F, et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine (AWARD-2). Diabetes Care. 2015;38:2241–2249. https://doi.org/10.2337/dc14-1625
  7. Dungan KM, et al. Once-weekly dulaglutide versus once-daily liraglutide (AWARD-6). Lancet. 2014;384:1349–1357. https://doi.org/10.1016/S0140-6736(14)60976-4
  8. Tuttle KR, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and CKD (AWARD-7). Lancet Diabetes Endocrinol. 2018;6:605–617. https://doi.org/10.1016/S2213-8587(18)30104-9
  9. Gerstein HC, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). Lancet. 2019;394:121–130. https://doi.org/10.1016/S0140-6736(19)31149-3
  10. Frias JP, et al. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus 1.5 mg (AWARD-11). Diabetes Care. 2021;44:765–773. https://doi.org/10.2337/dc20-1473
  11. Nicholls SJ, et al. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes (SURPASS-CVOT). N Engl J Med. 2025;393:2409–2420. https://doi.org/10.1056/NEJMoa2505928
  12. Arslanian SA, et al. Once-weekly dulaglutide for the treatment of youths with type 2 diabetes (AWARD-PEDS). N Engl J Med. 2022;387:433–443. https://doi.org/10.1056/NEJMoa2204601
  13. European Medicines Agency. Good pharmacovigilance practices: current modules, including I, VI, VII and IX, and the implementation notices for amended legislation and ICH E2D(R1). https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/good-pharmacovigilance-practices-gvp
  14. European Commission. Commission Implementing Regulation (EU) 2025/1466 of 22 July 2025, amending Implementing Regulation (EU) No 520/2012 on performance of pharmacovigilance activities. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32025R1466

Regulatory Note

Sources and product information reviewed on 26 October 2026 (Asia/Kolkata). This article is educational and is not a substitute for clinical assessment or the current locally authorised prescribing information. US and EU labels may differ in indications, age coverage and safety language. Animal toxicology, clinical-trial endpoints, postmarketing reports, regulatory requirements and recommended operational practices are different categories of evidence and should not be conflated.

Revision History

QPPV.com